412 related articles for article (PubMed ID: 15522036)
41. Biotechnology's metamorphosis into a drug discovery industry.
Drews J
Nat Biotechnol; 1998 May; 16 Suppl():22-4. PubMed ID: 9591258
[No Abstract] [Full Text] [Related]
42. The role of natural product chemistry in drug discovery.
Butler MS
J Nat Prod; 2004 Dec; 67(12):2141-53. PubMed ID: 15620274
[TBL] [Abstract][Full Text] [Related]
43. Lack of development of new antimicrobial drugs: a potential serious threat to public health.
Norrby SR; Nord CE; Finch R;
Lancet Infect Dis; 2005 Feb; 5(2):115-9. PubMed ID: 15680781
[TBL] [Abstract][Full Text] [Related]
44. Discovery research: the scientific challenge of finding new antibiotics.
Livermore DM;
J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
[TBL] [Abstract][Full Text] [Related]
45. Future antibiotics scenarios: is the tide starting to turn?
Theuretzbacher U
Int J Antimicrob Agents; 2009 Jul; 34(1):15-20. PubMed ID: 19342202
[TBL] [Abstract][Full Text] [Related]
46. Drug discovery and natural products: end of an era or an endless frontier?
Li JW; Vederas JC
Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
[TBL] [Abstract][Full Text] [Related]
47. Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
O'Connor KA; Roth BL
Nat Rev Drug Discov; 2005 Dec; 4(12):1005-14. PubMed ID: 16341065
[TBL] [Abstract][Full Text] [Related]
48. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
49. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs.
Lister PD
Biochem Pharmacol; 2006 Mar; 71(7):1057-65. PubMed ID: 16316633
[TBL] [Abstract][Full Text] [Related]
50. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance.
Finch R;
J Antimicrob Chemother; 2011 Sep; 66(9):1945-7. PubMed ID: 21700629
[TBL] [Abstract][Full Text] [Related]
51. A decade of fragment-based drug design: strategic advances and lessons learned.
Hajduk PJ; Greer J
Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
[TBL] [Abstract][Full Text] [Related]
52. The business of developing antibacterials.
Fox JL
Nat Biotechnol; 2006 Dec; 24(12):1521-8. PubMed ID: 17160056
[TBL] [Abstract][Full Text] [Related]
53. The power of genomics to transform the biotechnology industry.
Haseltine WA
Nat Biotechnol; 1998 May; 16 Suppl():25-7. PubMed ID: 9591259
[No Abstract] [Full Text] [Related]
54. Genetic strategies for antibacterial drug discovery.
Miesel L; Greene J; Black TA
Nat Rev Genet; 2003 Jun; 4(6):442-56. PubMed ID: 12776214
[TBL] [Abstract][Full Text] [Related]
55. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
Infectious Diseases Society of America
Clin Infect Dis; 2010 Apr; 50(8):1081-3. PubMed ID: 20214473
[TBL] [Abstract][Full Text] [Related]
56. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
57. Monopoly pricing of an antibiotic subject to bacterial resistance.
Herrmann M
J Health Econ; 2010 Jan; 29(1):137-50. PubMed ID: 20015559
[TBL] [Abstract][Full Text] [Related]
58. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
59. The trials and tribulations of drug development for functional gastrointestinal disorders.
Chang L
Neurogastroenterol Motil; 2008 May; 20 Suppl 1():130-8. PubMed ID: 18402650
[TBL] [Abstract][Full Text] [Related]
60. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
